OnKure Therapeutics, Inc. Tangible Net Worth Ratio
OnKure Therapeutics, Inc. tangible net worth ratio. OnKure Therapeutics, Inc. (OKUR) has a Tangible Net Worth Ratio of 100.0% as of June 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($172.11 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See debt-free asset ratio of OnKure Therapeutics, Inc. to measure how much of total assets are equity-financed.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of OnKure Therapeutics, Inc. (2021–2025)
Tangible net worth ratio of OnKure Therapeutics, Inc. from 2021 to 2025. This chart shows how OnKure Therapeutics, Inc.'s Tangible Net Worth Ratio has changed across 3 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 100.0%, reflecting net assets of $172.11 Million with intangible assets of $0.00 USD. See OKUR working capital ratio to evaluate short-term liquidity relative to the company's equity base.
OnKure Therapeutics, Inc. Tangible Net Worth Ratio by Year (2021–2025)
OnKure Therapeutics, Inc. tangible net worth ratio by year from 2021 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for OnKure Therapeutics, Inc. from 2021 to 2025, covering 3 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see OnKure Therapeutics, Inc. market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | $56.18 Million | $0.00 | $62.12 Million | ▲ +0.0 pp |
| 2024 | 100.0% | $103.83 Million | $0.00 | $114.91 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $147.21 Million | $0.00 | $154.02 Million | — |